Gardani, C.F.F.; Pedrazza, E.L.; Paz, V.S.; Zanirati, G.G.; da Costa, J.C.; Andrejew, R.; Ulrich, H.; Scholl, J.N.; Figueiró, F.; Rockenbach, L.;
et al. Exploring CD39 and CD73 Expression as Potential Biomarkers in Prostate Cancer. Pharmaceuticals 2023, 16, 1619.
https://doi.org/10.3390/ph16111619
AMA Style
Gardani CFF, Pedrazza EL, Paz VS, Zanirati GG, da Costa JC, Andrejew R, Ulrich H, Scholl JN, Figueiró F, Rockenbach L,
et al. Exploring CD39 and CD73 Expression as Potential Biomarkers in Prostate Cancer. Pharmaceuticals. 2023; 16(11):1619.
https://doi.org/10.3390/ph16111619
Chicago/Turabian Style
Gardani, Carla Fernanda Furtado, Eduardo Luiz Pedrazza, Victória Santos Paz, Gabriele Goulart Zanirati, Jaderson Costa da Costa, Roberta Andrejew, Henning Ulrich, Juliete Nathali Scholl, FabrÃcio Figueiró, Liliana Rockenbach,
and et al. 2023. "Exploring CD39 and CD73 Expression as Potential Biomarkers in Prostate Cancer" Pharmaceuticals 16, no. 11: 1619.
https://doi.org/10.3390/ph16111619
APA Style
Gardani, C. F. F., Pedrazza, E. L., Paz, V. S., Zanirati, G. G., da Costa, J. C., Andrejew, R., Ulrich, H., Scholl, J. N., Figueiró, F., Rockenbach, L., & Morrone, F. B.
(2023). Exploring CD39 and CD73 Expression as Potential Biomarkers in Prostate Cancer. Pharmaceuticals, 16(11), 1619.
https://doi.org/10.3390/ph16111619
